Zoetis ZTS · Analysis & News
Heads-up: USD Core CPI y/y is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD CPI y/y is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI m/m is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD CPI is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD CPI m/m is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI n.s.a. m/m is due in 4 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI is due in 4 h (high impact). The outlook can shift noticeably around it.
News situation · 0 items / 30 D
Economic data for ZTS
Full calendarComing up
- TodayUSDCore CPI y/y●●●Forecast 2.8%Previous 2.6%in 4h
- TodayUSDCPI y/y●●●Forecast 4.2%Previous 3.7%in 4h
- TodayUSDCore CPI m/m●●●Forecast 0.2%Previous 0.3%in 4h
- TodayUSDCPI●●●Forecast 338.683Previous 336.298in 4h
- TodayUSDCPI m/m●●●Forecast 0.5%Previous 0.6%in 4h
- TodayUSDCore CPI n.s.a. m/m●●●Previous 0.4%in 4h
- TodayUSDCore CPI●●●Forecast 339.796Previous 338.896in 4h
- November 12, 2026USDInitial Jobless Claims●●●in 2 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
Both worlds over time
Technical and news signals of the last 90 days on one timeline.
ZTS fundamental outlook
From news analysis — different time windows than the trading horizons above · as of 11.09.2026
- ZTS has declined 51.1% over the past 52 weeks, a steeper drop than rival IDEXX's 33% slide from highs.
- Q2 2026 earnings guidance was revised downward due to safety perception concerns with Librela and delayed next-gen product launches until 2027.
- A June 2026 screwworm case in Texas briefly lifted ZTS via surging options volume, but this bullish catalyst has fully faded.
- Persistent negative safety perceptions among veterinarians regarding Librela remain the primary risk factor for near-term revenue.
- The delay in new product commercialization removes a key growth catalyst until at least 2027, extending the earnings recovery timeline.
- Two of the three signals are bearish with impact scores of 5 and 7, while the lone bullish signal is three months old and event-specific.
Zoetis shares have been under severe pressure, collapsing 51.1% over the past 52 weeks as of September 2026. The most recent signal confirms the stock's decline has outpaced even rival IDEXX, driven by a slowdown in veterinary clinic traffic. The primary catalyst for the sell-off was a downward revision to near-term earnings guidance in Q2 2026, triggered by persistent safety perception concerns surrounding the canine arthritis drug Librela and a delay in next-generation product launches until 2027. This bearish narrative has overwhelmed a brief bullish spike in June 2026, when a confirmed screwworm case in Texas drove surging options volume on expectations of increased demand for Zoetis' parasitic treatments. That event-driven optimism proved short-lived against the structural headwinds of product safety doubts and a thinning pipeline. The weight of evidence points to continued negative sentiment, with no immediate catalysts to reverse the Librela overhang or accelerate the delayed product launches. The market is pricing in a prolonged earnings reset, with the stock's 50% annual decline reflecting deep skepticism about management's ability to restore growth in the near term.
59 days ago · Based on 3 signals
📝 Overview Generated automatically
ZTS has been the subject of 3 signals across 3 articles in the last 365 days. Sentiment skews Bearish (67%).
Breakdown: 1 bullish, 2 bearish, 0 neutral.
Most-cited catalysts: Confirmed screwworm case in Texas (1×), Surging options volume in Zoetis (1×), Potential recovery in sales if safety perception concerns regarding Librela are addressed (1×). Most-cited risk factors: Uncertainty over the outbreak's extent (1×), General market risk appetite could shift away from event-driven trades (1×), Continued negative safety perceptions among veterinarians regarding Librela (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.